Research in Diabetes Therapy demonstrates that individuals diagnosed with both type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) show markedly improved kidney survival rates when their average serum uric acid levels remain under 360 μmol/L, along with a 37% reduced chance of serious kidney-related complications.
Researchers analyzed data from 1,072 patients across eight medical centers and discovered that kidney risk escalated sharply beyond the threshold, with the most pronounced advantage seen in individuals with an eGFR of 30–59 mL/min/1.73 m².
Participants were followed for an average of 60.4 months. The study examined if TA-SUA levels affected long-term kidney outcomes. These included doubling of serum creatinine, dialysis, kidney transplantation, or progression to ESKD.
At the start of the study, hyperuricemia was present in 46.1% of participants, with a higher prevalence among men (50.4%) than women (37.9%). The study used Cox proportional hazards regression models, cubic spline analysis, propensity score matching (PSM), subgroup analyses, and sensitivity analyses to ensure the robustness of the findings.
The results showed that patients who maintained a TA-SUA level below 360 μmol/L experienced significantly better renal survival than those whose long-term uric acid levels remained at or above this threshold, with an adjusted hazard ratio of 0.63 (95% confidence interval: 0.41–0.98; P=0.038).
Subgroup analyses focused on patients with moderately diminished kidney function. These patients benefited most from keeping TA-SUA below 360 μmol/L. Stricter uric acid management could help preserve kidney function in this group.
The study’s findings were published in the journal Diabetes Therapy, with the researchers concluding that maintaining a TA-SUA level below 360 μmol/L may be a useful therapeutic target for improving kidney outcomes in patients with T2DM and CKD.
Leave a Reply